Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced the expansion of its strategic plan to further develop the company’s exosome platform technologies. In conjunction with these efforts, Stephen Gould, Ph.D. has been appointed as Executive Consultant to guide Capricor’s development of exosome-based vaccines and exosome-based therapeutics.

Company management will host a conference call and webcast with slides to discuss its financial results and provide a general business update at 4:30 p.m. (ET) on the same day. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment and prevention of diseases.

-To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and.

The panel will include an interactive discussion moderated by Jason McCarthy, Ph.D., Maxim Group Senior Managing Director, Biotechnology. Among the topics to be discussed are how cell therapy can treat acute respiratory distress syndrome, or ARDS, a significant contributor to higher mortality in COVID-19.

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Is (CAPR) Outperforming Other Medical Stocks This Year?

-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that.

Linda Marbán became the CEO of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2010. First, this article will compare CEO...

Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release its financial results for the fourth quarter and full year ended December 31, 2019, shortly after the NASDAQ market close on Wednesday, March 18. Management will then host a webcast and conference call at 4:30 p.m. ET on March 18.

Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway. CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity and is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration.

Investors of micro-cap biotech Capricor (CAPR) were probably raising a glass or two last week, as the stock skyrocketed by 253% in one session. The share price surge came following the release of promising results for a possible COVID-19 treatment.The company’s lead candidate CAP-1002, an allogeneic cardiac stem cell therapy, demonstrated 100% success when given to 6 critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS). The patients were treated on a compassionate care basis and over the course of 1 month. Following the infusion, within one to five days, 4 of the 5 patients receiving mechanical ventilation no longer required support. The fifth has yet to be weaned off ventilation support, while the sixth is being treated with supplemental oxygen and is clinically stable.The FDA has now authorized an expansion of the access protocol to include up to 20 patients. Capricor plans to advance with a randomized, placebo-controlled trial in moderate to severe patients, with non-equity capital providing the requisite funds.Maxim analyst Jason McCarthy argues allogeneic cell therapies “are powerful immune modulators,” which are demonstrating “compelling data in ARDS.”McCarthy noted, “Cell therapy (though the data is early) is emerging as a potentially important COVID-19 therapeutic. Capricor makes the third cell therapy to demonstrate high rates of survival among the sickest COVID-19 patients (those with ARDS on mechanical ventilation). ARDS is the real killer in COVID-19 and studies in NYC hospital networks have reported mortality rates as high as 88% in patients on ventilators.”Despite the encouraging data, McCarthy warns that as the trial is small, “one can consider the data anecdotal.”However, the positive readout is reason enough for the analyst to boost his price target for the microcap from $4 to $10, while keeping his "buy" rating intact. (To watch McCarthy’s track record, click here)Only one other analyst has been tracking Capricor’s progress over the last 3 months. The additional Buy rating provides the biotech with a Moderate Buy consensus rating. The average price target hits $9.50 and implies potential upside of 40% over the next 12 months. (See Capricor stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. More recent articles from Smarter Analyst: * 3 Biotech Stocks Under $4 With at Least 50% Upside Potential * Sanofi CEO Says Americans to Get Potential Virus Vaccine First * Amazon Urges Congress to Establish a Law Against Price Gouging * Cisco Shares Up Pre-Market After Topping Quarterly Profit Bets

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shareholders should be happy to see the share price up 27% in the last week...

Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced that it will host a Key Opinion Leader (KOL) call on the cardiac complications of DMD on Wednesday, April 15, 2020 at 1:30 pm Eastern Time. The call will feature a presentation by key opinion leader Michael Taylor, M.D., Ph.D. (Cincinnati Children's Hospital), Director of Advanced Imaging Innovation. Dr. Taylor will provide an overview of Duchenne muscular dystrophy, particularly focusing on the cardiac complications of the disease, its progression and current cardiac treatment options.

Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announced that it will host a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action.

Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of.

Capricor Therapeutics Inc.'s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy was released.What Happened Six critically ill COVID-19 patients were treated with CAP-1002, a new cell therapy currently being developed for the treatment of Duchenne muscular dystrophy (DMD). All the patients were treated at Cedars-Sinai Medical Center in Beverly Hills, California, and were suffering from acute respiratory distress syndrome (ARDS). Four of the six patients have now been discharged.After a review of the available data, the U.S. Food and Drug Administration has approved Capricor's expanded access protocol to treat up to 20 additional COVID-19 patients with CAP-1002.Dr. Linda Marban, the chief executive of Capricor, said in a statement, "CAP-1002 is an easy-to-deliver intravenous therapy that has been administered successfully to over 150 patients to date. Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients."Why It Matters The company has reported no adverse effects related to the infusion of CAP-1002 from among the six COVID-19 patients.Four of the six patients no longer required ventilator support within 1-4 days of receiving the CAP-1002 treatment.Capricor shares closed more than 250% higher on Wednesday, the same day the treatment data was released. The clinical-stage biotechnology company, which had a minuscule market cap of $10.16 million at the beginning of April, was predicted to achieve a triple-digit market capitalization by analysts. At press time, the company's market cap stood at 101.95 million.Price Action Capricor Therapeutics shares traded 3.65% lower at $8.19 in the after-hours session on Wednesday. The shares had closed the regular session 252.70% higher at $8.50.See more from Benzinga * Barclays Q1 Net Profit Erodes By 42%, Bank To Take Up .6B Credit Impairment Charge * Alphabet Shares Rise During Earnings Call As Q1 Advertising Revenue Better Than Expected * Buyout Hopes Raised As Blackstone Picks Up 0M Stake In Australian Casino Operator Crown(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Capricor Therapeutics, Inc. (NASDAQ:CAPR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 ...

In the compassionate care cases, five male patients and one female patient (between ages 19 and 75) suffering from COVID-19 received IV infusions of 150 million allogeneic cardiosphere-derived cells (CAP-1002). In DMD, the lack of dystrophin produces abnormal inflammatory responses, which are responsible for much of the damage to skeletal and cardiac muscle.

With a market cap of a miniscule $10.16 million, you can firmly place biotech Capricor Therapeutics (CAPR) in the nano cap section. Although, according to one analyst, if recent developments are anything to go by, the Beverly Hills, California based company won’t be in the small fry category for much longer.H.C. Wainwright’s Joseph Pantginis reiterated a Buy on Capricor along with a $9.00 price target. The implication for investors? Potential upside of a humungous 737%. (To watch Pantginis’s track record, click here)So, what is driving an analyst to set such an extravagant target for such a tiny player? Well, among other reasons, Capricor is one of the companies fighting back against the coronavirus on multiple fronts, both with a search for a vaccine and a possible treatment.Last Friday, Capricor announced that under the compassionate use pathway, CAP-1002, its novel cell therapy currently in clinical development for the treatment of Duchenne muscular dystrophy (DMD), is being used to treat patients with advanced COVID-19. So far, two patients at Cedars Sinai Hospital in Los Angeles have received the treatment and both are presently clinically stable.“We note that both patients were in critical condition before receiving CAP-1002 and, according to the compassionate use pathway, they had exhausted all options for treatment. We remind investors that for drugs being administered under compassionate use, the FDA can immediately collect information and make the appropriate decisions about the safety and efficacy of those experimental treatments.” Pantginis said.In the coming weeks, more patients are expected to receive the experimental treatment, while discussions are currently taking place regarding a formal clinical trial. Additionally, the FDA is currently reviewing Capricor’s Investigational New Drug (IND) application to investigate the use of CAP-1002 in certain COVID-19 patients.The news comes following last month’s KOL (key opinion leader) event which discussed Capricor’s partnership with Dr Stephen Gould, a leader in the field of exosome biology, to develop exosome-based vaccines against COVID-19.The two teams are currently testing two exosome-vaccine candidates (in non-human primates and small animals), with the hope that an IND can be filed either in the third or fourth quarter.Although Pantginis reminds investors that usually “the gold standard for vaccine development is proven protection from infection,” the urgent need could result in a faster than usual process.The analyst said, “In the context of the COVID-19 emergency, we expect that long and expensive studies, while are still required for traditional vaccine strategies, may not be needed for all approaches, providing solid scientific evidence of safety and efficacy in stimulating specific immunity. Capricor is planning to accumulate detailed results of both humoral and cellular immune responses from vaccinated subjects, which could potentially accelerate the regulatory process.”Over the last three months, there has been only one further analyst to throw the hat in with a view on Capricor’s prospects. The additional Buy rating means the small biotech currently holds a Moderate Buy consensus rating. At $6.50, the average price target implies possible upside of a sky scraping 507%. (See Capricor stock analysis on TipRanks)